5-MeO-pyr-T

Use and effects

In his book TiHKAL, Alexander Shulgin gives the dose of 5-MeO-pyr-T as 0.5 to 2mg orally and its duration as "several hours". It was also assessed at doses of 1 to 4mg smoked.

The drug's effects were dose-dependent and variably included intense tinnitus (ear ringing), nausea and vomiting, miosis (pupil constriction), confusion or cognitive impairment, uncomfortableness, minor dysphoria, partial to complete amnesia, flailing, rolling about, quivering, and shaking, unconsciousness, and prolonged hangover. Reports of psychedelic-like effects were mixed, ranging from producing no closed-eye visuals and none of the "shifting shapes, colors and forms" of dimethyltryptamine (DMT) or the clarity or energy of 5-MeO-DMT, to producing a rush, being "intense but not terrifying", initially 5-MeO-DMT-like, ego death, full body buzz, humming resonance, and feeling that "God is love". Other notable comments included "absolute poison", "never again", "very negative", "felt as if the top of my head was blown off", user's actions being scary and others being alarmed, wandering the streets in a fugue state, and the drug being "some weird-ass shit". Its effects have also been described as "white-out" analogously to 5-MeO-DMT and with amplified amnesic effects compared to 5-MeO-DMT.

The effects of 5-MeO-pyr-T appear to be highly variable between individuals. It was described as being very different from other psychedelics and it was emphasized that a trip sitter is essential for 5-MeO-pyr-T. Shulgin has also described 5-MeO-pyr-T as being "not hallucinogenic" and instead as producing "long-lived amnesia and unconsciousness".

Interactions

Pharmacology

Pharmacodynamics

5-MeO-pyr-T shows very high affinity for the serotonin 5-HT1A receptor and much lower affinity or activity at other assessed serotonin receptors. At the serotonin 5-HT1A receptor, it had an affinity (Ki) of 0.577nM and an activational potency () of 2.40nM. These values were respectively 646-fold and 34-fold more potent than at the serotonin 5-HT2A receptor (Ki = 373nM, EC50 = 13.5–81.3nM (depending on assay), = 92%). In other studies, it was a partial agonist of the serotonin 5-HT2A receptor, with an EC50 of 692nM and an Emax of 73%. In addition, it was a partial agonist of the serotonin 5-HT4 receptor in the rat esophagus, with an EC50 of 355nM and an Emax of 53%. The drug has also been predicted to bind to the serotonin 5-HT7 receptor, with a predicted affinity (Ki) of 631nM. In one study, relative to 5-MeO-DMT, 5-MeO-pyr-T had 12-fold greater activational potency at the serotonin 5-HT1A receptor and 3-fold reduced activational potency at the serotonin 5-HT2A receptor, with 38-fold increased selectivity for the serotonin 5-HT1A receptor over the serotonin 5-HT2A receptor.

Besides the serotonin receptors, 5-MeO-pyr-T is very weakly active at the serotonin transporter (SERT). It showed an affinity (Ki) for the SERT of 3,006nM and an inhibitory potency () in terms of serotonin reuptake inhibition of 2,765nM. Additionally, 5-MeO-pyr-T is a substrate of the SERT and acts as a partial serotonin releasing agent in HEK293 cells, with an EC50 of 5,700nM.

In early literature, 5-MeO-pyr-T was described as the most potent tryptamine yet evaluated in the open-field test, but as also having high toxicity that would likely preclude evaluation in humans. In subsequent modern studies, 5-MeO-pyr-T produced effects in rodents including the head-twitch response (a behavioral proxy of psychedelic effects), hypothermia, and hypolocomotion. Its median effective dose (ED50) for producing the head-twitch response was slightly higher than that of 5-MeO-DMT (7.29mg/kg vs. 4.84mg/kg, respectively), whereas it was much less efficacious in inducing the response compared to 5-MeO-DMT and produced only a weak maximal effect (10.0 events vs. 38.1events, respectively). 5-MeO-pyr-T was also similarly potent as 5-MeO-DMT in producing hypothermia and hypolocomotion, but conversely showed greater maximal responses for both of these effects.

Chemistry

Synthesis

The chemical synthesis of 5-MeO-pyr-T has been described.

Analogues

Analogues of 5-MeO-pyr-T include pyr-T, 4-HO-pyr-T, 4-F-5-MeO-pyr-T, 5-MeO-DMT, and 5-MeO-DET, among others. Analogues of 5-MeO-pyr-T (pyrrolidine) with different rings, including 5-MeO-pip-T (piperidine) and 5-MeO-mor-T (morpholine), are also known, but have not been tested in humans.

History

5-MeO-pyr-T was first characterized by Mitzal by 1962. Animal studies were later published by Hunt and Brimblecombe in 1967. The effects of 5-MeO-pyr-T in humans were described by Alexander Shulgin in his book TiHKAL in 1997. Robert Oberlender, from the lab of David E. Nichols at Purdue University, is known to have accidentally taken too high of a dose of 5-MeO-pyr-T and wandered outside in a fugue state.{{cite podcast | url=https://www.patreon.com/posts/podcast-26-with-55228463 | archive-url=https://www.youtube.com/watch?v=x9WmEVRxebE | archive-date=19 August 2022 | title=PODCAST 26: An interview with Vyvanse inventor Dr. Robert Oberlender | website=The Hamilton Morris Podcast | publisher=Patreon | host=Hamilton Morris | date=22 August 2021 | time=9:44–12:59, 1:16:00–1:32:23, 1:32:24–1:34:32 | access-date=15 June 2025 | quote=[Morris:] Another instance of this would be Oberlender's overdose on 5-methoxypyrrolidine-tryptamine, which I think is one of the most fascinating stories in underground psychedelic scientific research and one that has never been told publicly before this conversation. I don't wanna spoil it, but I think it's an example of how you can look in the scientific literature and you can see oh 5-methoxypyrrolidine-tryptamine, hmmm, it's a potent psychedelic. But until a human being tries it, you don't really know what it is. And this turned out to be quite an unusual molecule. Not a classical psychedelic by any stretch of the imagination. It induces something closer to a dissociative fugue. And I remember reading these reports in TiHKAL and thinking, for one, these reports are not written by Shulgin. [...]}} His experience was later included as the highest-dose 5-MeO-pyr-T experience report in TiHKAL. The drug was encountered as a novel designer and recreational drug in Europe by 2017. 5-MeO-pyr-T's pharmacology was more fully characterized in modern studies in 2009, 2023, and 2024.

Society and culture

Legal status

Canada

5-MeO-pyr-T is a controlled substance in Canada.

United States

5-MeO-pyr-T is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

References

References

1. (1975). "Hallucinogenic Agents". Wright-Scientechnica.
2. (2003). "Hallucinogens: A Forensic Drug Handbook". Elsevier Science.
3. (1997). "TiHKAL, The Continuation". Transform Press.
4. (August 2024). "Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties". Molecular Psychiatry.
5. (2023). "5-MeO-MET, 5-MeO-DET and 5-MeO-pyr-T strongly bind to 5-HT1A and 5-HT2A receptors and act as partial SERT substrates". Neuroscience Applied.
6. Prainer, Bianca-Cristine. (2009). "Tryptamin-Derivate als 5-HT4-Rezeptorliganden: Synthese und in-vitro-Pharmakologie".
7. (2003). "Characterization of the 5-HT₇ Receptor. Determination of the Pharmacophore for 5-HT₇ Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site". Journal of Medicinal Chemistry.
8. (1962). "N/A". Dissertationes Pharm.
9. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry.
10. "EMCDDA–Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA".
11. "Analytics Report: 5-MeO-pyr-T (C15H20N2O)". Nacionalni Forenzični Laboratorij.
12. (5 December 2025). "Controlled Drugs and Substances Act".
13. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.